Yeojung Moon

Senior Managing Director at IMM Investment

Speaker

Dr. Yeojung Moon is a passionate investor at IMM Investment with various early-to-late stage investment experiences in bio and healthcare. As the first MD into the venture capital industry, she has guided various early-stage bio and healthcare startups to establish and grow their business into global scale. Leveraging her clinical and research experience at Yonsei Severance Hospital as an OBGYN doctor, she has been recognized as an early-detector of differentiated technology and hands-on supporter to her portfolio partners. Her track record is accentuated by her distinctive contribution to Lunit (KOSDAQ:A32813) as a multi-time investor and a board member(aka Lunit’s Mom) to realize their mission to “Conquer Cancer through AI”

Currently she manages the IMM Salus fund #1($66mn), IMM Salus fund #2($43mn) and IMM Start-up fund#1($110mn) focusing in biotech, healthcare and deep tech.

Portfolio

Orum therapeutics (Dual-Precision Targeted Protein Degradation (TPD²)), Curocell(CD19 CAR-T), Nextbiomedical(hemostatic system of GI bleeding), IMBiologics(bispecific Ab for immune dz),Lunit(AI CDSS), Kai healthcare(AI for IVF-ET), Mediwhale(AI for eye and CVD), Rebellions(AI chip) , etc

She holds a board seat of Hanwha Investment & Securities Co., Ltd.(KOSPI: 003530), Orum Therapeutics and is a selected member of Presidential committee of Korea’s 4th industrial revolution.

Prior to joining IMM, Dr. Moon led Bio investment division at InterVest. She was also an assistant professor at Yonsei Severance Hospital. Yeojung holds PhD in Neuroscience and MD from Yonsei University.